Literature DB >> 33572717

Test-Retest Reliability of the Patient Activation Measure-13 in Adults with Substance Use Disorders and Schizophrenia Spectrum Disorders.

Katrine Melby1,2,3, Mona Nygård4,5,6, Mathias Forsberg Brobakken4,5, Rolf W Gråwe4,6, Ismail Cüneyt Güzey4,6, Solveig Klæbo Reitan4,6, Einar Vedul-Kjelsås4,6, Jørn Heggelund7, Mariela Loreto Lara-Cabrera4,6,8.   

Abstract

Patient Activation Measure-13 (PAM-13) is a valid and widely used questionnaire that assess an individual's knowledge, confidence, and skills for self-management of their chronic illness. Although there is some evidence regarding its reliability, the test-retest reliability has not been investigated among patients with substance use disorders (SUDs) or schizophrenia spectrum disorders. We investigated the internal consistency and test-retest reliability of PAM-13 in these populations. Test-retest reliability was analysed using data from 29 patients with SUDs and 28 with schizophrenia spectrum disorders. Cronbach's α and Intraclass Correlation Coefficient (ICC) scores were used to examine internal consistency and test-retest reliability, respectively. Of the 60 collected test-retest questionnaires, 57 were included in the analyses. No mean differences between time one (T1) and time two (T2) were observed in either patient group, except for item 12 in schizophrenia spectrum disorders patients (p < 0.05). Internal consistency for T1 and T2 was 0.75 and 0.84 in SUDs patients and 0.87 and 0.81 in schizophrenia spectrum disorders patients, respectively. The ICC was r = 0.86 in patients with SUDs and r = 0.93 in patients with schizophrenia spectrum disorders. To conclude, PAM-13 showed good internal consistency and test-retest reliability in SUDs and schizophrenia spectrum disorders patients.

Entities:  

Keywords:  internal consistency; patient activation measure-13; schizophrenia spectrum disorders; self-management; substance use disorder; test–retest reliability

Year:  2021        PMID: 33572717      PMCID: PMC7908201          DOI: 10.3390/ijerph18031185

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  33 in total

1.  The effect of a brief educational programme added to mental health treatment to improve patient activation: A randomized controlled trial in community mental health centres.

Authors:  Mariela L Lara-Cabrera; Øyvind Salvesen; Merete Berg Nesset; Carlos De las Cuevas; Valentina Cabral Iversen; Rolf W Gråwe
Journal:  Patient Educ Couns       Date:  2015-12-02

2.  The role of patient activation in psychiatric visits.

Authors:  Michelle P Salyers; Marianne S Matthias; Crystal L Spann; Jennifer M Lydick; Angela L Rollins; Richard M Frankel
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

3.  Patients with schizophrenia have impaired muscle force-generating capacity and functional performance.

Authors:  Mona Nygård; Mathias Forsberg Brobakken; Ragnhild Bjerkem Roel; Joshua Landen Taylor; Solveig Klaebo Reitan; Ismail Cüneyt Güzey; Gunnar Morken; Einar Vedul-Kjelsås; Eivind Wang; Jørn Heggelund
Journal:  Scand J Med Sci Sports       Date:  2019-08-18       Impact factor: 4.221

4.  Dual diagnosis of mental illness and substance use disorder and injury in adults recently released from prison: a prospective cohort study.

Authors:  Jesse T Young; Ed Heffernan; Rohan Borschmann; James R P Ogloff; Matthew J Spittal; Fiona G Kouyoumdjian; David B Preen; Amanda Butler; Lisa Brophy; Julia Crilly; Stuart A Kinner
Journal:  Lancet Public Health       Date:  2018-04-18

5.  Adaptation and validation of the German Patient Activation Measure for adolescents with chronic conditions in transitional care: PAM® 13 for Adolescents.

Authors:  Franziska Bomba; Henriette Markwart; Holger Mühlan; Ingo Menrath; Gundula Ernst; Ute Thyen; Silke Schmidt
Journal:  Res Nurs Health       Date:  2017-12-20       Impact factor: 2.228

6.  Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study.

Authors:  Marina Davoli; Anna M Bargagli; Carlo A Perucci; Patrizia Schifano; Valeria Belleudi; Matthew Hickman; Giuseppe Salamina; Roberto Diecidue; Federica Vigna-Taglianti; Fabrizio Faggiano
Journal:  Addiction       Date:  2007-12       Impact factor: 6.526

Review 7.  Rehabilitation of schizophrenic patients.

Authors:  S Gunatilake; J Ananth; S Parameswaran; S Brown; W Silva
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

8.  Reduced peak oxygen uptake and implications for cardiovascular health and quality of life in patients with schizophrenia.

Authors:  Jørn Heggelund; Jan Hoff; Jan Helgerud; Geir E Nilsberg; Gunnar Morken
Journal:  BMC Psychiatry       Date:  2011-12-05       Impact factor: 3.630

9.  Adaptation of a patient activation measure (PAM) into Turkish: reliability and validity test.

Authors:  Cansu Kosar; Dilek Buyukkaya Besen
Journal:  Afr Health Sci       Date:  2019-03       Impact factor: 0.927

10.  Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden.

Authors:  Merete Nordentoft; Kristian Wahlbeck; Jonas Hällgren; Jeanette Westman; Urban Osby; Hassan Alinaghizadeh; Mika Gissler; Thomas Munk Laursen
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

View more
  1 in total

1.  Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above.

Authors:  Zsombor Zrubka; Péter Vékás; Péter Németh; Ágota Dobos; Ottó Hajdu; Levente Kovács; László Gulácsi; Judith Hibbard; Márta Péntek
Journal:  Eur J Health Econ       Date:  2022-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.